Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
|Articles|March 14, 2018
The Impact of Psychiatric-Rheumatic Comorbidity
Are you prepared to recognize and treat anxiety, depression, and other comorbid psychiatric disorders when they arise in your patients?
Advertisement
References1. Liew J, Lucas Williams J, Dobscha S, Barton JL. Posttraumatic stress disorder and correlates of disease activity among veterans with ankylosing spondylitis. Rheumatol Int. 2017;37:1765-1769.2. Marrie RA, Hitchon CA, Walld R, et al. Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res. 2018 Feb 13. doi:10.1002/acr.23539.3. Tiosano S, Nir Z, Gendelman O, et al. The association between systemic lupus erythematosus and bipolar disorder-a big data analysis. Eur Psychiatry. 2017;43:116-119.
Advertisement
Related to this article
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.
Advertisement
Advertisement